| Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study. | |
| | |
MedLine Citation:
|
PMID: 20429689 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Regression of left ventricular (LV) hypertrophy and albuminuria in hypertension has previously been shown to reduce clinical cardiovascular events and death. We aimed to investigate the associations of regression of electrocardiographic (ECG) LV hypertrophy and albuminuria with the incidence of revascularization. METHODS: In 9193 hypertensive patients included in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, we measured urine albumin/creatinine ratio (UACR), LV hypertrophy by electrocardiography, serum high-density lipoprotein (HDL) cholesterol, and blood pressure after 2 weeks of placebo treatment and yearly during 5 years of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen. The incidence of coronary and peripheral revascularization was recorded. RESULTS: In Cox regression analyses adjusted for treatment allocation and continent, high time-varying Sokolow-Lyon voltage (hazard ratio [HR]=1.01 [1.00-1.02], p=0.01), but not time-varying Cornell product or UACR, predicted coronary revascularization together with low time-varying HDL-cholesterol, low time-varying pulse pressure, high Framingham risk score and history of angina pectoris. Adjusted for treatment allocation and continent, high time-varying Sokolow-Lyon voltage (HR=1.01 [1.00-1.03], p=0.02), but not time-varying Cornell product or UACR, predicted peripheral revascularization together with high time-varying pulse pressure, high Framingham risk score, history of peripheral vascular disease and prior myocardial infarction. CONCLUSION: Higher Sokolow-Lyon voltage during antihypertensive treatment, but not UACR or the Cornell voltage-duration product, was independently associated with higher incidence of coronary as well as peripheral revascularization. |
| | |
Authors:
|
Camilla L Søraas; Kristian Wachtell; Peter M Okin; Björn Dahlöf; Richard B Devereux; Theis Tønnessen; Sverre E Kjeldsen; Michael H Olsen |
Related Documents
:
|
17481639 - Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowerin... 15619409 - Relation of diurnal blood pressure variation and triglyceride-to-high-density lipoprote... 7975129 - A nine-year chronic toxicity study of cadmium in monkeys. ii. effects of dietary cadmiu... 15858939 - High diastolic blood pressure during exercise is associated with hypercholesterolemia i... 3405529 - What should be done about hypercholesterolaemia? 2883879 - Effects of beta blockers and other antihypertensive drugs on cardiovascular risk. 10523369 - Responses to acute changes in arterial pressure on renal medullary nitric oxide activit... 7911559 - Evidence for norepinephrine cardiotoxicity mediated by superoxide anion radicals in iso... 2996099 - The effects of volume loading during epidural analgesia. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Blood pressure Volume: 19 ISSN: 1651-1999 ISO Abbreviation: Blood Press. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-20 Completed Date: 2010-08-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9301454 Medline TA: Blood Press Country: England |
Other Details:
|
Languages: eng Pagination: 145-51 Citation Subset: IM |
Affiliation:
|
Oslo University Hospital, Ullevaal, Oslo, Norway. camillalare@yahoo.no |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Albuminuria / complications, drug therapy, urine Angina Pectoris / complications, drug therapy Antihypertensive Agents / pharmacology, therapeutic use Atenolol / pharmacology, therapeutic use Blood Pressure / drug effects Cholesterol, HDL Electrocardiography / adverse effects Humans Hypertension* / complications, drug therapy, physiopathology Hypertrophy, Left Ventricular / complications, drug therapy*, physiopathology* Incidence Losartan / pharmacology, therapeutic use Regression Analysis Risk |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Cholesterol, HDL; 114798-26-4/Losartan; 29122-68-7/Atenolol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ablative erbium:YAG laser treatment of idiopathic chronic inflammatory non-cicatricial balanoposthit...
Next Document: Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in tr...